Affiliation: Stanford University
- Late pregnancy suppresses relapses in experimental autoimmune encephalomyelitis: evidence for a suppressive pregnancy-related serum factorAnnette Langer-Gould
Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA
J Immunol 169:1084-91. 2002..In conclusion, serum from late pregnancy has the capacity to down-regulate T cell responses and might be associated with the amelioration of disease activity in experimental autoimmune encephalomyelitis...
- Interferon-gamma-producing T cells, pregnancy, and postpartum relapses of multiple sclerosisAnnette Langer-Gould
Department of Health Research and Policy, School of Medicine, Stanford University, Stanford, CA 94305, USA
Arch Neurol 67:51-7. 2010..To determine whether fluctuations in functional T-cell subsets can explain why multiple sclerosis (MS) relapses decline during pregnancy and increase in the postpartum period...
- Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosisAnnette Langer-Gould
Stanford University School of Medicine, HRP Redwood Bldg, Room T202 MC 5405, Stanford, CA 94305, USA
Arch Neurol 66:958-63. 2009..To determine if exclusive breastfeeding protects against postpartum relapses of multiple sclerosis (MS) and, if so, whether this protection is related to prolonged lactational amenorrhea...
- Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic reviewAnnette Langer-Gould
Department of Health Research and Policy, Stanford University School of Medicine, Stanford, CA 94305, USA
Arch Neurol 63:1686-91. 2006..To identify clinical and demographic factors associated with long-term disability in patients with relapsing-remitting multiple sclerosis...
- Progressive multifocal leukoencephalopathy and multiple sclerosis: lessons from natalizumabAnnette Langer-Gould
Stanford University School of Medicine, HRP Redwood Building, Room T202, MC 5405, Stanford, CA 94305, USA
Curr Neurol Neurosci Rep 6:253-8. 2006..Finally, we discuss what additional natalizumab efficacy data need to be presented before any decisions should be made about treating RRMS patients with a high risk of developing long-term disability...
- Progressive multifocal leukoencephalopathy in a patient treated with natalizumabAnnette Langer-Gould
Department of Neurology, Stanford University School of Medicine, Stanford, Calif, USA
N Engl J Med 353:375-81. 2005..The patient was treated with systemic cytarabine, and two months later, his condition had improved...
- Strategies for managing the side effects of treatments for multiple sclerosisAnnette Langer-Gould
Department of Neurology and Neurological Sciences, Stanford University Medical Center, Hospital and Clinic, Stanford, California, USA
Neurology 63:S35-41. 2004..Patients should be encouraged to communicate with their physicians so that side effects can be managed promptly. This article describes and provides management strategies for side effects associated with MS treatments...
- What went wrong in the natalizumab trials?Annette Langer-Gould
Department of Health Research and Policy, Stanford University School of Medicine, CA94305, USA
Lancet 367:708-10. 2006
- B-cell depletion with rituximab in relapsing-remitting multiple sclerosisStephen L Hauser
Department of Neurology, University of California at San Francisco, San Francisco, CA 94143 0114, USA
N Engl J Med 358:676-88. 2008..There is increasing evidence that B lymphocytes are involved in the pathogenesis of multiple sclerosis, and they may be a therapeutic target. Rituximab, a monoclonal antibody, selectively targets and depletes CD20+ B lymphocytes...
- Absence of neuromyelitis optica IgG antibody in an active relapsing-remitting multiple sclerosis populationCraig H Smith
Genentech Corporation CHS, South San Francisco, California, USA
J Neuroophthalmol 29:104-6. 2009..We resolved to test for NMO antibody in a population of patients with active relapsing-remitting (RR) MS...
- Gray matter N-acetyl aspartate deficits in secondary progressive but not relapsing-remitting multiple sclerosisElfar Adalsteinsson
Department of Radiology, Stanford University School of Medicine, Stanford, CA, USA
AJNR Am J Neuroradiol 24:1941-5. 2003....
- Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitisChristopher Lock
Department of Neurology and Neurological Sciences, Beckman Center, Stanford University, Stanford, California, USA
Nat Med 8:500-8. 2002..These results in EAE corroborate the microarray studies on MS lesions. Large-scale analysis of transcripts in MS lesions elucidates new aspects of pathology and opens possibilities for therapy...
- Pregnancy and the Modulation of Multiple SclerosisAnnette Langer Gould; Fiscal Year: 2006..The search for the pregnancy-related factor or hormone responsible for the protective effect of pregnancy in MS may potentially lead to the development of novel treatments for MS and other Th1-driven autoimmune diseases. ..